20% rise, page-12

First 12 Last

Share
Profile

Follow
bundybo7

421 Posts.

28

02/05/17

07:38

Post #: 24397842
Share

Originally posted by Matt Adl ↑

Just went over where they are at and financials, there are few key points of contention that could determine a good entry point.

1st at 0.006 a share the orders are stacked @26m making it unlikely you will get in unless you buy at 0.007.

2nd DMX-200 with a 50% probability of clinical success - these figures need to improve somewhat through the testing phase as customers and doctors are going to prefer a higher % of success.

3rd product can license to a pharma partner in FY19 (base case) or FY18 (optimistic case) for US$30-50m upfront, US$100-200m in milestones and an 8-12% royalty. Finding a pharma partner and developing an upfront revenue followed by MS+R agreement is not guaranteed on these figures, if this translates succesfully your looking at estimated 13-30c company minimal; however, this is at least 1-2 years off.

4th product launch in FSGS in FY22 (base case) or FY21 (optimistic case) in the US and FY23 (base case) or FY22 (optimistic case) in Europe - long way till product launch, creating little interest in the stock or chance at recouping investment, it would be a MT/Long play for sure

5th company raises another $10m at $0.01 per share in order to complete both halves of the current Phase 2 for DMX-200 as well as move other pipeline elements forward - this seems like the best time for a short play, if you can acquire at 0.007 and they plan to CR at 0.01 translates to .3 raise; however, looking at current turnover, not sure how the SP will hit that target unless the subscription is to SI only.

Bio-pharma is highly speculative with significantly high peaks with substantial down-turns between, this company is still a fair way off and I would predict closer to the end of the year may be a better accumulation point if you don't want capital tied up. Right now it would be a pure punt, but if your keen on it give it a go and see how it turns out, will keep my eye on it and see how the company progresses.

Expand

Matt i like your work, always informative , interesting and backed up with research ,

Last edited by bundybo7: 02/05/17

QBL Price at posting: 2.3¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

There are more pages in this discussion • 5 more messages in this thread...

First 12 Last

Add CGB (ASX) to my watchlist

20% rise, page-12

Top Stories

Red Mountain Mining: record gold prices, two projects, two greenstone belts

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Featured News